观察了普萘洛尔和血管紧张素Ⅱ(AT-Ⅱ)对胃癌单克隆抗体3H11和丝裂霉素(MMC)交联物导向治疗的增强作用。在荷瘤裸鼠体内观察,交联物的抑瘤率达50％,联合应用普萘洛尔或AT-Ⅱ,可使抑瘤率分别提高到79％和60％。从~(131)Ⅰ-3H11,在荷瘤裸鼠体内的生物学分布实验中也看到,普萘洛尔或AT-Ⅱ均能提高肿瘤组织对~(131)Ⅰ-3H11的摄取量。此结果表明,血管活性物质确可通过改善肿瘤血管的血流灌注,增加肿瘤内交联物含量,增强导向治疗的疗效。 To observe the enhancing effect of propranolol and angiotensin Ⅱ (AT-Ⅱ) on the targeted therapy of gastric cancer monoclonal antibody 3H11 and mitomycin (MMC). In tumor-bearing nude mice, the inhibition rate of the conjugate was 50%. Combined propranolol or AT-Ⅱ could increase the inhibitory rate to 79% and 60% respectively. From 131I-3H11, the biological distribution of tumor-bearing nude mice also showed that propranolol or AT-Ⅱ could increase the uptake of 131I-3H11 in tumor tissues. This result shows that vasoactive substances can indeed improve the curative effect of guiding therapy by improving the blood perfusion of tumor vessels, increasing the content of intra-tumor cross-linking compounds.